ArticleScandinavian journal of medicine & science in sports2025
Percutaneous Closure of Patent Foramen Ovale and Atrial Septal Defect in Athletes: A Study With a Long-Term Follow-Up.
Article in Scandinavian journal of medicine & science in sports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management.MedComm · 2026Review
- Article
- Percutaneous Closure of Patent Foramen Ovale and Atrial Septal Defect in Athletes: A Study With a Long-Term Follow-Up.Scandinavian journal of medicine & science in sports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patent foramen ovale (PFO) and atrial septal defect (ASD) percutaneous closure is routinely performed. However, data on long-term safety and efficacy in athletes are lacking. This study with a long-term follow-up investigated the safety and efficacy of percutaneous PFO/ASD closure in athletes compared to non-athletes, focusing on the impact of sports participation on complications. The study included individuals < 50 years old undergoing percutaneous PFO/ASD closure. Athletes practiced sports for ≥ 4 h/week for ≥ 2 consecutive years before and after the procedure. Periprocedural complications, device dislocation, and bleeding events were assessed during a long-term follow-up (mean 10.6 ± 5.1 years). Echocardiography, including transcranial Doppler bubble test, was performed before discharge, at 1 and 3 months, and yearly thereafter. Seventy-six patients (36 athletes and 40 non-athletes) were included. Fourteen patients practiced sports at risk of trauma, and no differences in periprocedural complications were observed between the two groups. During the follow-up, no device dislocation was observed in athletes. A single major bleeding occurred in a non-athlete during dual antiplatelet therapy (DAPT). Eight minor bleedings occurred (4 during DAPT, 4 during single antiplatelet therapy-SAPT), with no significant difference between athletes and non-athletes (p = 0.23 and p = 0.79, respectively). One minor sports-related bleeding (muscular hematoma) occurred during SAPT in an athlete practicing kickboxing. Percutaneous PFO/ASD closure is safe in athletes, with no differences in complication rates between athletes and non-athletes observed during long-term follow-up (> 10 years). Sports participation did not significantly increase the bleeding risk, even in athletes practicing sports at risk of trauma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.